169 related articles for article (PubMed ID: 36919403)
21. Bayesian single-to-double arm transition design using both short-term and long-term endpoints.
Xu T; Shi H; Lin R
Pharm Stat; 2023; 22(4):588-604. PubMed ID: 36755420
[TBL] [Abstract][Full Text] [Related]
22. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
Moatti M; Chevret S; Zohar S; Rosenberger WF
Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
[TBL] [Abstract][Full Text] [Related]
23. Bayesian two-stage design for phase II oncology trials with binary endpoint.
Chen L; Pan J; Wu Y; Wang J; Chen F; Zhao J; Chen P
Stat Med; 2022 May; 41(12):2291-2301. PubMed ID: 35178729
[TBL] [Abstract][Full Text] [Related]
24. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
Jiang L; Li R; Yan F; Yap TA; Yuan Y
Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
[TBL] [Abstract][Full Text] [Related]
25. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
Dong G; Shih WJ; Moore D; Quan H; Marcella S
Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
[TBL] [Abstract][Full Text] [Related]
26. Statistical tests for two-stage adaptive seamless design using short- and long-term binary outcomes.
Takahashi K; Ishii R; Maruo K; Gosho M
Stat Med; 2022 Sep; 41(21):4130-4142. PubMed ID: 35713225
[TBL] [Abstract][Full Text] [Related]
27. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
[TBL] [Abstract][Full Text] [Related]
28. A Bayesian predictive sample size selection design for single-arm exploratory clinical trials.
Teramukai S; Daimon T; Zohar S
Stat Med; 2012 Dec; 31(30):4243-54. PubMed ID: 22807115
[TBL] [Abstract][Full Text] [Related]
29. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
30. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Zhou H; Lee JJ; Yuan Y
Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
[TBL] [Abstract][Full Text] [Related]
31. A comparison of clinical development pathways to advance tuberculosis regimen development.
Chang V; Phillips PPJ; Imperial MZ; Nahid P; Savic RM
BMC Infect Dis; 2022 Dec; 22(1):920. PubMed ID: 36494644
[TBL] [Abstract][Full Text] [Related]
32. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
[TBL] [Abstract][Full Text] [Related]
33. A practical guide to Bayesian group sequential designs.
Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
[TBL] [Abstract][Full Text] [Related]
34. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
Guo B; Li D; Yuan Y
Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
[TBL] [Abstract][Full Text] [Related]
35. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
36. Bayesian adaptive design for pediatric clinical trials incorporating a community of prior beliefs.
Wang Y; Travis J; Gajewski B
BMC Med Res Methodol; 2022 Apr; 22(1):118. PubMed ID: 35448963
[TBL] [Abstract][Full Text] [Related]
37. Bayesian basket trial design with false-discovery rate control.
Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
[TBL] [Abstract][Full Text] [Related]
38. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
Guo B; Li Y
BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
[TBL] [Abstract][Full Text] [Related]
39. A novel Bayesian adaptive design incorporating both primary and secondary endpoints for randomized IIB chemoprevention study of women at increased risk for breast cancer.
Gajewski BJ; Kimler BF; Koestler DC; Mudaranthakam DP; Young K; Fabian CJ
Trials; 2022 Dec; 23(1):981. PubMed ID: 36471449
[TBL] [Abstract][Full Text] [Related]
40. Statistical inference for response adaptive randomization procedures with adjusted optimal allocation proportions.
Zhu H
J Biopharm Stat; 2017; 27(5):732-740. PubMed ID: 27937121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
